articleTop 1% cited

MAINTENANCE BACILLUS CALMETTE-GUERIN IMMUNOTHERAPY FOR RECURRENT TA, T1 AND CARCINOMA IN SITU TRANSITIONAL CELL CARCINOMA OF THE BLADDER: A RANDOMIZED SOUTHWEST ONCOLOGY GROUP STUDY

The Journal of Urology · 2000 · Vol. 163(4) · pp. 1124–1129

Donald L. Lamm✉(The University of Texas System)Brent A. Blumenstein(The University of Texas System)John D. Crissman(The University of Texas System)James E. Montie(The University of Texas System)James E. Gottesman(The University of Texas System)Bruce A. Lowe(The University of Texas System)Michael F. Sarosdy(The University of Texas System)ROBERT D. BOHL(The University of Texas System)H. Barton Grossman(The University of Texas System)Thomas Beck(The University of Texas System)Joseph T. Leimert(The University of Texas System)E. David Crawford(The University of Texas System)

View via DOI Publisher page

Abstract

Compared to standard induction therapy maintenance BCG immunotherapy was beneficial in patients with carcinoma in situ and select patients with Ta, T1 bladder cancer. Median recurrence-free survival time was twice as long in the 3-week maintenance arm compared to the no maintenance arm, and patients had significantly longer worsening-free survival.

Bladder and Urothelial Cancer Treatments Urinary and Genital Oncology Studies Urologic and reproductive health conditionsMedicineTransitional cell carcinomaImmunotherapyCarcinoma in situOncologyInternal medicineUrologyCarcinomaBladder cancerCancer

MeSH terms

Adjuvants, ImmunologicAgedBCG VaccineUrinary Bladder NeoplasmsCarcinoma in SituCarcinoma, Transitional CellFemaleHumansImmunotherapyMaleMiddle AgedNeoplasm Recurrence, LocalNeoplasms, Multiple Primary

Citations

1,298

FWCI

45.54

field-weighted impact

References

Percentile

100%

vs. same field & year

Citations per year

Cited by

Guideline for the Management of Nonmuscle Invasive Bladder Cancer (Stages Ta, T1, and Tis): 2007 Update